FINWIRES · TerminalLIVE
FINWIRES

$UTHR

84 stories mentioning UTHRUpdated 2d ago

Every FINWIRES story that references UTHR, newest first.

What are analysts saying about UTHR?

Recent broker actions mentioned in FINWIRES coverage. Compiled from wire headlines; not investment advice.

What's the latest news on UTHR?

Insider Trading

United Therapeutics Insider Sold Shares Worth $4,772,295, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on September 10, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,772,295. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000139/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,740,795, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on September 08, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,740,795. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000137/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,647,354, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on September 04, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,647,354. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000136/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,883,839, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on September 01, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,883,839. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000133/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,855,312, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 31, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,855,312. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000132/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,863,730, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 24, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,863,730. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000127/xslF345X05/primarydocument.xml

$UTHR
Sectors

Sector Update: Healthcare Stocks Rise Pre-Bell Monday

Healthcare stocks were rising pre-bell Monday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.4% and the iShares Biotechnology ETF (IBB) gaining 0.2%.Guardant Health (GH) lost a $245.2 million patent infringement lawsuit filed by TwinStrand Biosciences and the University of Washington, TwinStrand said. Guardant Health stock was down more than 2% premarket.United Therapeutics (UTHR) shares were up more than 1% after the company said the US Food and Drug Administration accepted its new drug application for ralinepag to treat pulmonary arterial hypertension.Regenxbio (RGNX) stock was down more than 21% after the company said it does not plan to resubmit the biologics license application for its investigational gene therapy RGX-121 for Hunter syndrome in the near term following a US Food and Drug Administration clinical hold.

$GH$IBB$RGNX$UTHR$XLV
Wire

United Therapeutics Says FDA Accepted Application for Pulmonary Arterial Hypertension Treatment

United Therapeutics (UTHR) said Monday the US Food and Drug Administration accepted its new drug application for ralinepag to treat pulmonary arterial hypertension.The regulatory agency set a target action date of June 24, 2027, for the proposed once-daily oral medication.The submission is based on phase 3 trial data showing the drug reduced the risk of clinical worsening by 55% compared with a placebo and met secondary goals for exercise capacity and heart failure biomarkers, it said.Shares of the company were down more than 1% in Monday premarket activity.Price: $513.12, Change: $-7.88, Percent Change: -1.51%

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,342,079, According to a Recent SEC Filing

Paul A Mahon, Executive Vice President & General Counsel, on August 20, 2026, sold 8,300 shares in United Therapeutics (UTHR) for $4,342,079. Following the Form 4 filing with the SEC, Mahon has control over a total of 45,172 common shares of the company, with 45,172 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000123158926000018/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,949,717, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 20, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,949,717. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000125/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,739,664, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 14, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,739,664. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000121/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,892,748, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 12, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,892,748. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000119/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,048,137, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 07, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,048,137. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000116/xslF345X05/primarydocument.xml

$UTHR
Wire

MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says

MannKind's (MNKD) increasingly diversified portfolio is seen bringing in higher revenue in H2, with 2026 being a "year of execution" on the commercial and clinical fronts, Wedbush said in a Thursday note.The company plans to prioritize its Furoscix therapy, with its ReadyFlow autoinjector delivery system priced at around the same level as the on-body infusor but with a 70% higher gross margin, the firm said. MannKind stated that 2026 total net revenue could be nearer to the lower end of guidance of $110 million, but the inventory buying pattern may impact H2 revenue significantly, according to the note.MannKind's partner United Therapeutics (UTHR) expects future demand for ralinepag DPI and Tyvaso DPI to require all of its manufacturing capacity, pointing to strong revenue potential, Wedbush said.Further, MannKind plans to focus on the pediatric market in the near term for Afrezza after the drug's approval from the US Food and Drug Administration in May, the firm said.Wedbush's rating on the company's stock is outperform with a price target of $8.Price: $3.81, Change: $-0.29, Percent Change: -7.07%

$MNKD$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,902,569, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on August 03, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,902,569. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000112/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,930,098, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 31, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,930,098. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000111/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,986,594, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson & CEO, on July 30, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,986,594. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000110/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $4,962,488, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 29, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $4,962,488. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000109/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,003,976, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 28, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,003,976. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000108/xslF345X05/primarydocument.xml

$UTHR
Insider Trading

United Therapeutics Insider Sold Shares Worth $5,038,971, According to a Recent SEC Filing

Martine A Rothblatt, Director, Chairperson and Chief Executive Officer, on July 27, 2026, sold 9,500 shares in United Therapeutics (UTHR) for $5,038,971. Following the Form 4 filing with the SEC, Rothblatt has control over a total of 668,728 common shares of the company, with 40,513 shares held directly and 628,215 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1082554/000110657826000107/xslF345X05/primarydocument.xml

$UTHR

Showing 1-20 of 84

Track with the FINWIRES app suite

FolioX
FolioX
Track UTHR in your portfolio
WheelAI
WheelAI
Analyze UTHR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on UTHR